Long-Acting Shot Preferred to Oral Therapy in 2 HIV Studies

By Marie Rosenthal

SEATTLE—Results from two phase 3 studies show that an investigational long-acting injectable treatment with a two-drug regimen had similar efficacy to a daily, oral three-drug regimen in adults living with HIV.

The researchers provided 48-week data from the ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) studies of the novel, investigational, long-acting regimen of cabotegravir-rilpivirine (CAB/RPV), which is